GenBioPro

GenBioPro is a United States pharmaceutical company focused on the manufacture and distribution of generic pharmaceutical products, most notably generic mifepristone. Its principal product is used in medication-abortion care and has made the company a participant in the regulatory, legal, and public-policy debates surrounding access to abortion medication in the United States. The company entered the U.S. mifepristone market after receiving Food and Drug Administration authorization in 2019 to market a generic version of the drug. Before that authorization, Danco Laboratories was the only company distributing mifepristone in the United States. The approval therefore introduced a second manufacturer and distributor into a market that had previously depended on a single commercial supplier. GenBioPro's regulatory history was unusually lengthy. The company's application for approval was submitted in 2009, but authorization was not granted until 2019. This was substantially longer than the FDA's stated goal of reviewing generic-drug applications within approximately ten months, according to reporting cited in the company's Wikipedia article. The extended review period illustrates the exceptional regulatory and political sensitivity associated with mifepristone, although the available reference material does not establish all of the reasons for the delay. In 2023, GenBioPro sued the FDA seeking a legal judgment confirming that mifepristone could continue to be sold despite abortion restrictions enacted by some U.S. states. The lawsuit placed the company directly in a national dispute over federal drug approval, state abortion restrictions, and the continued availability of medication abortion. The litigation also underscored GenBioPro's role as a regulated pharmaceutical supplier rather than merely a commercial brand competing on consumer positioning. Publicly documented information in the supplied sources is concentrated on GenBioPro's mifepristone business, its FDA authorization, and its 2023 legal action. The available material does not identify a founder, headquarters, parent company, public listing, broader product portfolio, or named executives. Accordingly, this dossier treats GenBioPro primarily as a U.S. pharmaceutical company associated with generic mifepristone and does not infer additional corporate details.

GenBioPro is a U.S. pharmaceutical company associated primarily with generic mifepristone, a prescription medicine used in medication-abortion care. Its history, as documented in the supplied reference material, is closely tied to the lengthy federal approval process for its generic product and to subsequent litigation over the legal availability of mifepristone in the United States. The company submitted an application for approval of generic mifepristone in 2009. The application remained under review for approximately a decade. This was considerably longer than the FDA's stated objective of completing generic-drug application reviews in about ten months. The reference material does not provide a complete explanation for the delay, but the product's connection to abortion care placed the application in a particularly sensitive regulatory and political environment. In 2019, the FDA authorized GenBioPro to sell generic mifepristone in the United States. Before this approval, Danco Laboratories had been the only company distributing mifepristone domestically. GenBioPro's authorization consequently changed the structure of the U.S. market by adding another approved supplier. The approval also established the company as a significant participant in the pharmaceutical supply chain for medication abortion. The company's public significance increased during the national conflict over abortion restrictions. Following the adoption of anti-abortion laws in some states, questions arose concerning the relationship between federal approval of mifepristone and state efforts to limit or prohibit abortion medication. In 2023, GenBioPro sued the FDA in an effort to obtain a legal judgment confirming that mifepristone could continue to be sold. The action reflected the company's interest in preserving the commercial availability of its federally authorized product and placed it among the corporate actors directly engaged in the legal debate over medication abortion. The supplied sources provide little information about GenBioPro's internal organization, leadership, founding, ownership, headquarters, or products beyond generic mifepristone. No additional corporate history should be inferred from the company's involvement in the mifepristone market. Its documented history is therefore best understood through three stages: the 2009 application, the 2019 FDA authorization, and the 2023 lawsuit concerning continued sales.

• 2023

  Challenge to restrictions on mifepristone sales

  [1]GenBioProen.wikipedia.org

  GenBioPro sued the FDA seeking confirmation that its mifepristone product could continue to be sold despite abortion laws enacted by some states.

• 2019

  FDA authorization

  [1]GenBioProen.wikipedia.org

  The FDA authorized GenBioPro to sell a generic version of mifepristone, making it the second U.S. distributor of the drug after Danco Laboratories.

• 2009

  Application for generic mifepristone

  [1]GenBioProen.wikipedia.org

  GenBioPro submitted its application to obtain authorization to market generic mifepristone in the United States.

A U.S. generic-pharmaceutical company positioned around the manufacture and distribution of mifepristone, with its public profile shaped by FDA regulation and litigation concerning medication-abortion access.

• Medication-abortion pharmaceutical · 2019

  Generic mifepristone

  GenBioPro's documented flagship product is a generic version of mifepristone, a prescription medicine used in medication-abortion care. The product received FDA authorization in 2019 after a lengthy review process that began with the company's application in 2009. Its distribution has been central to GenBioPro's corporate identity and to the legal disputes concerning access to mifepristone in the United States.

• 2023

  Litigation to protect continued mifepristone salesOther

  Background

  Some U.S. states had enacted anti-abortion laws and legal challenges were raising questions about the continued availability of mifepristone despite its federal authorization.

  Action taken

  GenBioPro sued the FDA seeking a legal judgment confirming that mifepristone could continue to be sold.

  Aftermath

  The lawsuit made GenBioPro a direct corporate participant in the national legal and regulatory dispute over medication abortion. The supplied reference does not provide the final outcome.

  Source

1. 1GenBioProen.wikipedia.org